Neogenomics Inc.

NAS:NEO  
32.05
-0.55 (-1.69%)
StockTwits Share  Twitter Share  Facebook Share

Search For a Symbol

Market Cap (Intraday)3.29B
Current PE1,594.66
Forward PE 114.46
2yr Forward PE 86.62
See more stats...
Estimates Current Quarter
Revenue$104.25 Million
Adjusted EPS$0.06
See more estimates...
10-Day MA$31.34
50-Day MA$27.26
200-Day MA$23.62
See more pivots...

NEOGENOMICS INC Stock, NAS:NEO

12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS, FL 33913
United States of America
Phone: 9419231949
Number of Employees: 938

Description

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.